Foresite Capital Management V, LLC
Long book
$271.0M
Q1 2026
Positions
9
Top-10 weight
100%
concentration
Last quarter
+17.9%
SPY +14.8%
Turnover
40%
of book per quarter
Strategy in plain words
auto-generated from filingsForesite Capital Management V, LLC is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $271.0M US long book across 9 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: ALUMIS INC, CG ONCOLOGY INC, DISC MEDICINE INC, HIMS & HERS HEALTH INC, EIKON THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 7.5pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+3.1%
Q2 2024
-8.1%
Q3 2024
-7.4%
Q4 2024
-13.1%
Q1 2025
-12.2%
Q2 2025
+41.6%
Q3 2025
+37.0%
Q4 2025
+49.4%
Q1 2026
+17.9%
Sector allocation
Healthcare 100%
Long book by quarter
What does Foresite Capital own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| ALMS ALUMIS INC | Healthcare | 5.9M | $129.9M | 47.9% | +2.0% |
| CGON CG ONCOLOGY INC | Healthcare | 1.0M | $68.0M | 25.1% | Held |
| IRON DISC MEDICINE INC | Healthcare | 374.1K | $23.9M | 8.8% | +25.1% |
| HIMS HIMS & HERS HEALTH INC | Healthcare | 738.2K | $15.3M | 5.7% | +170.2% |
| EIKN EIKON THERAPEUTICS INC | Healthcare | 1.3M | $14.0M | 5.1% | New |
| LYEL LYELL IMMUNOPHARMA INC | Healthcare | 477.1K | $9.6M | 3.5% | Held |
| PHVS PHARVARIS NV | Healthcare | 194.1K | $5.5M | 2.0% | New |
| NRIX NURIX THERAPEUTICS INC | Healthcare | 265.0K | $4.1M | 1.5% | New |
| MAZE MAZE THERAPEUTICS INC | Healthcare | 25.9K | $773K | 0.3% | -70.0% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 9 | $271.0M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 7 | $164.4M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 6 | $108.7M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 12, 2025 | 6 | $80.7M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 6 | $87.6M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 6 | $120.2M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 5 | $143.9M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 13, 2024 | 5 | $156.6M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 5 | $106.5M | canonical | SEC ↗ |